Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (9.986.186 €): European Proteomics Infrastructure Consortium providing Access Hor01.01.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
European Proteomics Infrastructure Consortium providing Access
In life sciences research, proteomics technologies promise to be even more revolutionary than genomics for understanding the molecular mechanisms of complex biological systems and their (mal-)functions in health and disease. As a result, there is a strongly growing need for the integration of proteomic technologies into world-class life sciences research programs in medicine, agriculture, food, biotechnology, and materials. The European Proteomics Infrastructure Consortium providing Access (EPIC-XS) brings together a consortium of world-leading, highly innovative European proteomics facilities with the shared goal of supporting excellent life sciences research in Europe. This will be achieved by providing access to cutting-edge proteomics facilities, and by developing and implementing novel mass spectrometry based proteomics and bioinformatics approaches to shape the future life sciences research in Europe. The Transnational Access in EPIC-XS consists of around 2400 days of access to state-of-the-art proteomics facilities, corresponding to around 150 user projects, which will be evaluated by an independent review panel to ensure excellence, and to match users with the best facility for their challenging research questions. The cutting-edge Joint Research Activities in EPIC-XS are built on the extremely strong innovation track record of the consortium members, and will address bottlenecks in, and develop novel approaches for, future-oriented efforts in computational and structural proteomics, analysis of higher-order proteome organization, multi-omics integration, and translational/clinical proteomics and personalized/precision medicine. EPIC-XS will provide users with unrivalled access to world-leading facilities and expertise, while simultaneously extending Europe’s leading international role in the. EPIC-XS meets the widespread current demands for user access, addresses present bottlenecks in the field and will open up entirely new perspectives in proteomics.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Centre National de la Recherche Scientifique Cnrs | 0,00 € |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | 209.750 € |
| EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH | 1.202.916 € |
| 266.750 € | |
| Forschungsinstitut für Molekulare Pathologie GmbH | 208.500 € |
| 523.349 € | |
| 480.782 € | |
| 70.500 € | |
| Institut Pasteur | 499.282 € |
| Istituto Europeo DI Oncologia Srl | 488.125 € |
| Kobenhavns Universitet | 1.206.964 € |
| Kungliga Tekniska Hoegskolan | 473.313 € |
| Masarykova Univerzita | 0,00 € |
| Mikrobiologicky Ustav AV CR V.V.I | 474.125 € |
| TECHNISCHE UNIVERSITAET MUENCHEN | 524.203 € |
| Tartu Ulikool | 70.500 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 120.500 € |
| Universiteit Utrecht | 1.745.001 € |
| Universitetet I Bergen | 70.500 € |
| VIB VZW | 1.351.127 € |
Quelle: https://cordis.europa.eu/project/id/823839
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Centre National de la Recherche Scientifique Cnrs - EU-Förderung (9.986.186 €): European Proteomics Infrastructure Consortium providing Access"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
